Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer

Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer

This prospective, phase II study evaluated novel biomarkers as predictors of response to bevacizumab in patients with breast cancer (BC), using serial imaging methods and gene expression analysis. Patients with primary stage II/III BC received bevacizumab 15 mg/kg (cycle 1; C1), then four cycles of...

Full description

Bibliographic Details
Main Authors: José Manuel López-Vega, Isabel Álvarez, Antonio Antón, José Juan Illarramendi, Antonio Llombart, Valentina Boni, María José García-Velloso, Josep María Martí-Climent, Luis Pina, Jesús García-Foncillas
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
bevacizumab
breast cancer biomarkers
dynamic contrast-enhanced magnetic resonance imaging
positron emission tomography
vascular endothelial growth factor receptor-2
Online Access:https://www.mdpi.com/2072-6694/13/14/3511

Internet

https://www.mdpi.com/2072-6694/13/14/3511

Similar Items